Alon Zadok Weizer MD MS, CPE (He/Him)
Minimally Invasive Surgery, Surgical Oncology
Chief Medical Officer/ Senior Vice President Mount Sinai Medical Center, Miami Beach, FL
Join to View Full Profile
Mount Sinai Medical Center4300 Alton RdMiami Beach, FL 33140
Phone+1 305-674-2957
Fax+1 305-674-2408
Dr. Weizer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alon Weizer, based in Miami Beach, FL, is a urologist with subspecialties in minimally invasive surgery and surgical oncology. He completed his medical residency in surgery and urology at Duke University Hospital, after graduating from Baylor College of Medicine in 1999. He serves as the Senior Vice President at Mount Sinai Medical Center and previously held the position of Chief Medical Officer at Chelsea Hospital. His expertise includes treatments for prostate cancer, gynecologic oncology, and performing procedures such as lymphadenectomy, ureteroscopy, and nephrectomy. Dr. Weizer has several publications in reputable journals like The Journal of Urology and European Urology, reflecting his research in urothelial carcinoma and surgical practices. He has led clinical trials on radical cystectomy and high-risk non-muscle invasive urothelial carcinoma treatments. He is recognized for multiple CMS Meaningful Use certifications from Epic Systems Corporation.
Education & Training
Duke University HospitalResidency, Urology, 2001 - 2005- Duke University HospitalResidency, Surgery, 1999 - 2001
Baylor College of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2022 - 2027
MI State Medical License 2004 - 2026
NC State Medical License 1999 - 2020
American Board of Urology Urology
American Association of Physician LeadershipCertified Physician Executive
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma Start of enrollment: 2009 Jan 01
- Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series.Anosh Dadabhoy, Chirag Doshi, Mazyar Zahir, Sanam Ladi-Seyedian, Domenique Escobar
Urologic Oncology. 2026-03-01 - 1 citationsLong-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.Phillip M Pierorazio, Nir Kleinmann, Ahmad Shabsigh, Brian Hu, Jay D Raman
The Journal of Urology. 2025-03-01 - 16 citationsIntegrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.Nathan M Merrill, Samuel D Kaffenberger, Liwei Bao, Nathalie Vandecan, Laura Goo
European Urology. 2024-11-01
Journal Articles
- Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic ImplicationsPetros Grivas, Phillip Palmbos, Ganesh Palapattu, Jeffrey S Montgomery, Alon Z Weizer, European Urology
- Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell CarcinomaAaron M Udager, Andrew S Mcdaniel, Simpa S Salami, Samuel D Kaffenberger, Jeffrey S Montgomery, Alon Z Weizer, Zachery R Reichert, Ajjai S Alva, Arul M Chinnaiyan, Sco..., European Urology
- Detailed Pathologic Analysis on the Co-Occurrence of Non-Seminomatous Germ Cell Tumor Subtypes in Matched Orchiectomy and Retroperitoneal Lymph Node DissectionsDavid Smith, Ganesh S Palapattu, Aaron Udager, Scott A Tomlins, Alon Z Weizer, Rohit Mehra, Angela Wu, Madelyn Lew, Jeffrey S Montgomery, Samuel D Kaffenberger, Khaled..., Medical Oncology
Authored Content
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Press Mentions
Why Are Maternity Wards Across South Florida Closing? There’s More Than One ReasonAugust 1st, 2025- Mount Sinai Medical Center Advances Chronic Disease Management with HealthSnap Remote Patient MonitoringJuly 1st, 2025
- Biden's Prostate Cancer Diagnosis Is Unusual but Not Unheard of, Doctors SayMay 20th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
